Future of the pharmaceutical sector in Poland
Is Poland an attractive place for foreign pharmaceutical companies to invest? This was the main question discussed during the debate for leaders of the medical and pharmaceutical industry entitled “The Future of Healthcare”, which took place on 26th March in the Bristol Hotel in Warsaw. Representatives of the sector gathered to discuss the future of the pharmaceutical industry, the national medicines policy, and the impact of technological development on the transformation of the industry.
The meeting was opened with a speech by dr n. farm. Leszek Borkowski, medicines market consultant for American investment funds, who emphasized that good cooperation is a mutually empathic relationship between partners, i.e. patients and pharmaceutical companies. The expert also argued that each medicine entering the reimbursement list should be carefully considered in terms of its therapeutic effectiveness and the accompanying adverse effects. Only on the basis of this knowledge can one effectively make a decision concerning treatment with a given agent.
The main part of the meeting was a panel discussion moderated by prof. dr hab. n. med. Krzysztof J. Filipiak – Vice-Rector for Internationalization, Promotion, and Development of the Medical University of Warsaw.
The first question concerning the national medicines policy and access to innovative medicines was addressed to Aldona Zygmunt, Stakeholder Engagement, CEE Oncology, International Public Affairs from Pfizer Polska, who stressed the importance of equal access to the market. Only then can one start working hard on an investment of an innovative company, starting from cooperation with the academic community, looking for start-ups and projects worth investing in. It was also pointed out that investment decisions are hindered by the lack of transitional moments for making the drug available to patients before its reimbursement.
The next speaker was Paul van Arkel, President of Novartis Poland, who began by drawing attention to the need to provide additional funding to healthcare. He did this in a very illustrative way by comparing healthcare to the best of cars, which would not be able to move even an inch without fuel. The President of Novartis Poland stressed, however, that he is optimistic about the future, as more and more money goes into the system from both the state and private investors. Novartis itself invested over PLN 700 million in Poland.
Similar issues were also discussed by the President of the Management Board of Polpharma Biuro Handlowe, Sebastian Szymanek, who pointed out that it is important to attract as many investments based on companies with their decision-making centers located in Poland as possible. The President also proved that Polpharma fully deserves the title of the national champion. The company has the largest production and the highest employment, and its measure of innovation is R&D expenditure at the level of PLN 200/300 million per year as well as 55 patents registered in 2016, which gave the company first place among commercial companies.
Tomasz Judycki, Vice President of the Management Board of Atende Medica, President of the Polish Chamber of Healthcare IT, referred to the moderator’s question concerning the state of computerization in healthcare and who will benefit most from it. “Computerization of healthcare in Poland is significantly delayed taking into account the experience of neighboring European countries. This will change slightly in September, as the e-prescription program will be launched all over the country” – said Tomasz Judycki. He stressed that these changes will mainly be beneficial for patients, whose problems with filling prescriptions will be eliminated, as well as for physicians, whose work will be significantly accelerated.
The legal and formal aspects as well as future tendencies were discussed by Jacek Myszko, legal counsel at the Sołtysiński Kawecki & Szlęzak law firm, who began by pointing to the positive trend of legislation keeping up with the revolutionary changes. The most important issues mentioned included: implementation of big data, automation of production, and all kinds of marriages between companies analyzing and collecting data in order to process it and derive patterns and trends based on the entire population.
At the end of the panel discussion, dr n. farm. Jerzy Borkowski took the floor and pointed out that the national medicines policy should be adjusted to the financial capabilities of the state and take into account the interests of all the entities involved.
In his summary of this inspiring debate, the moderator, prof. dr. hab. n. med. Krzysztof J. Filipiak, asked the speakers to list the most important problems of the medicines policy. The following answers were given, among others:
- Improving the effectiveness of healthcare without increasing its cost
- Legislation keeping up with changes
- Access to objective epidemiological data
- Finding effective reimbursement methods for medicines
- Reasonable and balanced spending on medicine
- Increasing computerization in small institutions and conducting trainings in issuing e-prescriptions
The main part of the debate ended with a speech by prof. Michał Kleiber, Chairman of the Council of EC, who stressed the importance of the topic discussed. According to the professor, the first half of the 20th century belonged to physics, the second half – to information and communication technology, while the first half of the 21st century will definitely belong to biomedicine.
Organizer: Executive Club
Honorary Patronage:Pharmaceutical Research Institute, Polish Medical Association, Polish Union of Pharmaceutical Industry Employers, Medical University of Warsaw
Main Partner: Pfizer Polska
Gold Partner: Polpharma S.A.,
Partners: Atende S.A., Coloplast, Cigno Consulting, Novartis Poland, Sołtysiński Kawecki & Szlęzak
Media Patrons: Biotechnologia.pl, CEO Magazyn, Diagnozujemy.pl, MedicalOnline.pl, medinwestycje.pl, MEDserwis.pl, Polish Market, Polityka Zdrowotna, poradnikzdrowie.pl, Portale Medyczne, Przemysł Farmaceutyczny, Świat Medycyny, Świat Przemysłu Farmaceutycznego
About Executive Club: Executive Club is a networking organization bringing together members of top management representing the most important Polish and international companies. Since 2005, the Club has assembled well-established business leaders, whose actions set standards in the development of the Polish economy. The Club organizes regular meetings for its members to provide them with opportunities for business networking and sharing ideas. For more information, please visit our website: www.executive-club.com.pl